CoChat

Abstract CT035: Pharmacokinetics (PK), safety, and tolerability of pembrolizumab with berahyaluronidase alfa administered subcutaneously Q3W in participants with advanced melanoma

The DOI matches its Crossref record.

Abstract

Background: Pembrolizumab is approved for use across multiple cancers at doses of 200 mg Q3W, 2 mg/kg Q3W, or 400 mg Q6W administered as an intravenous (IV) infusion. Alternative subcutaneous (SC) formulations can provide added convenience and flexibility in the clinic. MK-3475A is pembrolizumab with berahyaluronidase alfa (MK-5180), a variant of human hyaluronidase developed and manufactured by Alteogen Inc., for SC administration of pembrolizumab (hereafter referred to as “pembro SC”). The purpose of this arm of the phase 1, nonrandomized, multi-arm, open-label 3475A-C18 study is to generate the first clinical data for pembro SC administered Q3W, with PK exposure measures as the primary endpoint. PK data will be used to validate model-based predictions and confirm Q3W SC dosing regimen. Methods: In arm 4 of this phase 1 study (NCT05017012), adults with unresectable advanced melanoma received pembro SC 395 mg Q3W for up to 35 cycles. Using serum concentration data collected in cycles 1-6, the primary objective was to characterize the PK profile of pembro SC administered Q3W in cycle 1 and cycle 6 (steady state). Other objectives included the evaluation of anti-drug antibodies (ADA) against pembro SC (secondary), characterization of the safety and tolerability of pembro SC (secondary), and evaluation of the systemic concentrations of and ADA against MK-5180 (tertiary). Results: 44 participants were treated with pembro SC 395 mg. Median (range) age was 60 years (30-89) and 50% were male. Median (range) pembro PK exposure measures in cycle 1 and at steady state were: Cmax 34.1 µg/mL (10.6-63.7) and 80.7 µg/mL (30.9-162); Ctrough 21.1 µg/mL (9.7-40.5) and 54.6 µg/mL (21.7-123); AUC0-3wks 567 µg·day/mL (192-979) and 1446 µg·day/mL (604-3050); Tmax 5 days (2-10) and 4 days (2-8). ADAs against pembro were detected in 1 of 40 (3%) evaluable participants, with no effect on pembro exposure observed. No samples had detectable MK-5180 levels, and ADAs against MK-5180 were not detected. On physical exam, 9 (20.5%) participants had injection site AEs, most frequently erythema (n=4) and injection site reaction (n=2). All injection site reactions were nonserious, grade 1, and effectively managed. Eight (18%) participants had an immune-mediated AE, most commonly hypothyroidism (n=3, 7%). Conclusions: The PK exposures of pembro SC Q3W in this study were generally consistent with model-based predictions and with PK exposures for pembro SC 790 mg Q6W and pembro IV 200 mg Q3W dosing regimens, thereby validating the model and confirming 395 mg Q3W as a dosing regimen for pembro SC. The overall systemic safety profile of pembro SC Q3W was consistent with the known safety profile of pembrolizumab monotherapy. Citation Format: Corlia Coetzee, Richard Khanyile, Graham Cohen, Georgina McAdam, Cathryn Walton, Sze Wai Chan, Bernardo Rapoport, Christian Caglevic, Patricio Yañez, Mallika Lala, Gina Song, Julia W. Cohen, Carlos Rojas. Pharmacokinetics (PK), safety, and tolerability of pembrolizumab with berahyaluronidase alfa administered subcutaneously Q3W in participants with advanced melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT035.

Overview

Integrity signals

Registry

Crossref · 10.1158/1538-7445.am2025-ct035

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 2

Metadata

Authors
Coetzee, C., Khanyile, R., Cohen, G., McAdam, G., Walton, C., Chan, S. W., Rapoport, B., Caglevic, C., Yañez, P., Lala, M., Song, G., Cohen, J. W., & Rojas, C.
Affiliations
  • 1Cape Town Oncology Trials, Cape Town, South Africa;
  • Steve Biko Hospital (ZA)
  • Life Groenkloof Hospital (ZA)
  • 4Cancercare Rondebosch Oncology-Clinical Trials, Cape Town, South Africa;
  • 5Bay Oncology, Gqeberha, South Africa;
  • 6Sandton Oncology Medical Group, Sandton, South Africa;
  • The Medical Oncology Centre of Rosebank (ZA)
  • Fundación Arturo López Pérez (CL)
  • 9James Lind Centro de Investigación del Cáncer, Temuco, Chile;
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • 11Bradford Hill Investigación Clínica, Santiago, Chile.
Venue
Cancer Research
Published
2025-04-25
Volume
85
Issue
8_Supplement_2
Pages
CT035-CT035
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W4409822373
Cited by
2
References
0
Citations by year
2026: 1 · 2025: 1
Type
conference abstract
Language
en
Open access
closed
Locations
Cancer Research (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
pembrolizumab, subcutaneous administration, advanced melanoma, pharmacokinetics, dosing regimen, anti-drug antibodies, hyaluronidase, safety and tolerability, immune checkpoint inhibitors, steady-state exposure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abstract CT035: Pharmacokinetics (PK), safety, and tolerability of pembrolizumab with berahyaluronidase alfa administered subcutaneously Q3W in participants with advanced melanoma. https://app.cochat.ai/papers/10.1158/1538-7445.am2025-ct035
The paper
Coetzee, C., Khanyile, R., Cohen, G., McAdam, G., Walton, C., Chan, S. W., Rapoport, B., Caglevic, C., Yañez, P., Lala, M., Song, G., Cohen, J. W., & Rojas, C. (2025). Abstract CT035: Pharmacokinetics (PK), safety, and tolerability of pembrolizumab with berahyaluronidase alfa administered subcutaneously Q3W in participants with advanced melanoma. Cancer Research. https://doi.org/10.1158/1538-7445.am2025-ct035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.